Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells.

Literature DB >> 24007862

Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells.

Bin Jia¹, Edwin Choy, Gregory Cote, David Harmon, Shunan Ye, Quancheng Kan, Henry Mankin, Francis Hornicek, Zhenfeng Duan.

Abstract

Liposarcoma is the second most common soft tissue sarcoma in adults, but treatment options have been quite limited thus far. In this study, we investigated the functional and therapeutic relevance of cyclin-dependent kinase 11 (CDK11) as a putative target in liposarcoma. CDK11 knockdown by synthetic siRNA or lentiviral shRNA decreased cell proliferation, and induced apoptosis in liposarcoma cells. Moreover, CDK11 knockdown enhances the cytotoxic effect of doxorubicin to inhibit cell growth in liposarcoma cells. These findings suggest that CDK11 is critical for the growth and proliferation of liposarcoma cells. CDK11 may be a promising therapeutic target for the treatment of liposarcoma patients.

Entities: CellLine Chemical Disease Gene Species

Keywords: CDK11; Immunohistochemistry; Kinase; Liposarcoma; Tissue microarray

Mesh：

Substances：

Year: 2013 PMID： 24007862 PMCID： PMC4128631 DOI： 10.1016/j.canlet.2013.08.040

Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679

43 in total

1. The functional interaction between CDK11p58 and β-1,4-galactosyltransferase I involved in astrocyte activation caused by lipopolysaccharide.

Authors: Xiaojuan Liu; Chun Cheng; Bai Shao; Xiaohong Wu; Yuhong Ji; Xiang Lu; Aiguo Shen
Journal: Inflammation Date: 2012-08 Impact factor: 4.092

2. Cdk11-cyclinL controls the assembly of the RNA polymerase II mediator complex.

Authors: Julie Drogat; Valérie Migeot; Elise Mommaerts; Caroline Mullier; Marc Dieu; Harm van Bakel; Damien Hermand
Journal: Cell Rep Date: 2012-11-01 Impact factor: 9.423

3. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial.

Authors: Jason J Luke; David R D'Adamo; Mark A Dickson; Mary Louise Keohan; Richard D Carvajal; Robert G Maki; Elisa de Stanchina; Elgilda Musi; Samuel Singer; Gary K Schwartz
Journal: Clin Cancer Res Date: 2012-02-28 Impact factor: 12.531

4. Diagnosis, management, and outcome of patients with dedifferentiated liposarcoma systemic metastasis.

Authors: Markus P Ghadimi; Tariq Al-Zaid; John Madewell; Tingsheng Peng; Chiara Colombo; Aviad Hoffman; Chad J Creighton; Yiqun Zhang; Anna Zhang; Alexander J Lazar; Raphael E Pollock; Dina Lev
Journal: Ann Surg Oncol Date: 2011-05-26 Impact factor: 5.344

Review 5. Emerging drug profile: cyclin-dependent kinase inhibitors.

Authors: James S Blachly; John C Byrd
Journal: Leuk Lymphoma Date: 2013-07-29

6. Targeting hedgehog-GLI-2 pathway in osteosarcoma.

Authors: Wen Yang; Xianzhe Liu; Edwin Choy; Henry Mankin; Francis J Hornicek; Zhenfeng Duan
Journal: J Orthop Res Date: 2012-09-11 Impact factor: 3.494

7. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

Authors: Mark A Dickson; William D Tap; Mary Louise Keohan; Sandra P D'Angelo; Mrinal M Gounder; Cristina R Antonescu; Jonathan Landa; Li-Xuan Qin; Dustin D Rathbone; Mercedes M Condy; Yelena Ustoyev; Aimee M Crago; Samuel Singer; Gary K Schwartz
Journal: J Clin Oncol Date: 2013-04-08 Impact factor: 44.544

8. CHK2 kinase promotes pre-mRNA splicing via phosphorylating CDK11(p110).

Authors: H-H Choi; H-K Choi; S Y Jung; J Hyle; B-J Kim; K Yoon; E-J Cho; H-D Youn; J M Lahti; J Qin; S-T Kim
Journal: Oncogene Date: 2012-11-26 Impact factor: 9.867

9. Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation.

Authors: Zhenfeng Duan; Jianming Zhang; Edwin Choy; David Harmon; Xianzhe Liu; Petur Nielsen; Henry Mankin; Nathanael S Gray; Francis J Hornicek
Journal: Clin Cancer Res Date: 2012-07-12 Impact factor: 12.531

10. Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma.

Authors: Elizabeth G Demicco; Keila E Torres; Markus P Ghadimi; Chiara Colombo; Svetlana Bolshakov; Aviad Hoffman; Tingsheng Peng; Judith V M G Bovée; Wei-Lien Wang; Dina Lev; Alexander J Lazar
Journal: Mod Pathol Date: 2011-10-21 Impact factor: 7.842

25 in total

1. Identification and characterization of the BmCyclin L1-BmCDK11A/B complex in relation to cell cycle regulation.

Authors: Tai-Hang Liu; Yun-Fei Wu; Xiao-Long Dong; Cai-Xia Pan; Guo-Yu Du; Ji-Gui Yang; Wei Wang; Xi-Yan Bao; Peng Chen; Min-Hui Pan; Cheng Lu
Journal: Cell Cycle Date: 2017-03-20 Impact factor: 4.534

2. Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system.

Authors: Yong Feng; Slim Sassi; Jacson K Shen; Xiaoqian Yang; Yan Gao; Eiji Osaka; Jianming Zhang; Shuhua Yang; Cao Yang; Henry J Mankin; Francis J Hornicek; Zhenfeng Duan
Journal: J Orthop Res Date: 2014-10-27 Impact factor: 3.494

3. CDK11^p110 plays a critical role in the tumorigenicity of esophageal squamous cell carcinoma cells and is a potential drug target.

Authors: Yue Du; Dan Yan; Yongliang Yuan; Jian Xu; Suhua Wang; Zhiheng Yang; Weiyan Cheng; Xin Tian; Quancheng Kan
Journal: Cell Cycle Date: 2019-02-12 Impact factor: 4.534

4. Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel.

Authors: Xianzhe Liu; Yan Gao; Jacson Shen; Wen Yang; Edwin Choy; Henry Mankin; Francis J Hornicek; Zhenfeng Duan
Journal: Mol Cancer Ther Date: 2016-05-20 Impact factor: 6.261